1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

01/05/2022 | 06:31am EDT

HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.

A live webcast of the presentation may be accessed on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ or at https://jpmorgan.metameetings.net/events/healthcare22/sessions/40344-affimed/webcast?gpu_only=true&kiosk=true and will be available for 30 days following the event. For more information or to schedule a one-on-one meeting with Affimed management, please contact Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact

Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

 


All news about AFFIMED N.V.
05/12Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innat..
GL
05/09Affimed provides update on asco afm13-104 oral presentation
AQ
05/06Affimed Provides Update on ASCO AFM13-104 Oral Presentation
AQ
04/28Affimed announces clinical update and trial in progress posters at the annual meeting o..
AQ
04/27CORRECTING and REPLACING -- Affimed N.V.
AQ
04/27Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting o..
AQ
04/19Affimed announces closing of public offering of common shares and full exercise of unde..
AQ
04/18Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Unde..
AQ
04/13Affimed Prices Common Stock Offering at $4 Per Share
MT
04/13Affimed Prices $85 Million Public Offering
MT
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2022 35,7 M 37,2 M 37,2 M
Net income 2022 -101 M -105 M -105 M
Net cash 2022 89,0 M 92,6 M 92,6 M
P/E ratio 2022 -4,01x
Yield 2022 -
Capitalization 469 M 488 M 488 M
EV / Sales 2022 10,6x
EV / Sales 2023 12,4x
Nbr of Employees 197
Free-Float 96,7%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 3,14 €
Average target price 11,22 €
Spread / Average Target 257%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Commercial Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.-40.76%488
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601